Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celularity, Inc. stock logo
CELU
Celularity
$2.05
-3.8%
$2.80
$1.00
$5.22
$54.61M0.75168,307 shs65,180 shs
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.36
-2.1%
$1.42
$0.81
$1.84
$72.12M1.51497,113 shs439,219 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.65
-17.1%
$0.46
$0.25
$4.28
$45.14M-0.083.43 million shs18.47 million shs
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
$0.02
+19,900.0%
$0.02
$0.00
$0.07
$2.54M17.16,999 shs100 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celularity, Inc. stock logo
CELU
Celularity
-0.93%+4.41%-5.75%+0.95%-12.70%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-2.11%+0.72%-13.13%+10.32%-6.71%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+15.59%+60.93%+75.65%+100.66%-28.64%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
-99.00%0.00%-99.50%0.00%-95.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celularity, Inc. stock logo
CELU
Celularity
$2.05
-3.8%
$2.80
$1.00
$5.22
$54.61M0.75168,307 shs65,180 shs
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.36
-2.1%
$1.42
$0.81
$1.84
$72.12M1.51497,113 shs439,219 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.65
-17.1%
$0.46
$0.25
$4.28
$45.14M-0.083.43 million shs18.47 million shs
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
$0.02
+19,900.0%
$0.02
$0.00
$0.07
$2.54M17.16,999 shs100 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celularity, Inc. stock logo
CELU
Celularity
-0.93%+4.41%-5.75%+0.95%-12.70%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-2.11%+0.72%-13.13%+10.32%-6.71%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+15.59%+60.93%+75.65%+100.66%-28.64%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
-99.00%0.00%-99.50%0.00%-95.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celularity, Inc. stock logo
CELU
Celularity
2.00
Hold$6.00192.68% Upside
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
2.33
Hold$5.50304.11% Upside
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.78
Moderate Buy$4.86646.10% Upside
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VAXX, RVPH, PMVP, and CELU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/29/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$2.00
9/27/2025
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/19/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$3.00 ➝ $2.00
9/15/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetSpeculative Buy$14.00 ➝ $7.00
9/9/2025
Celularity, Inc. stock logo
CELU
Celularity
WBB Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$6.00
8/18/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00 ➝ $3.00
8/18/2025
Celularity, Inc. stock logo
CELU
Celularity
WBB Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageModerate Buy$6.00
(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celularity, Inc. stock logo
CELU
Celularity
$54.22M1.01N/AN/A$0.37 per share5.54
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/A$3.40 per shareN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$0.02 per shareN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/A$0.11 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celularity, Inc. stock logo
CELU
Celularity
-$57.89M-$3.18N/AN/A-165.22%-459.57%-57.71%11/5/2025 (Estimated)
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$58.71M-$1.57N/AN/AN/AN/A-47.94%-43.82%11/6/2025 (Estimated)
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$29.92M-$0.65N/AN/AN/AN/AN/A-259.17%11/13/2025 (Estimated)
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
-$56.93M-$0.45N/AN/AN/AN/AN/AN/A

Latest VAXX, RVPH, PMVP, and CELU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.40N/AN/AN/AN/AN/A
8/29/2025Q1 2025
Celularity, Inc. stock logo
CELU
Celularity
N/A-$1.02N/A-$1.02N/A$5.74 million
8/14/2025Q2 2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.15-$0.12+$0.03-$0.12N/AN/A
8/7/2025Q2 2025
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.39-$0.41-$0.02-$0.41N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celularity, Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celularity, Inc. stock logo
CELU
Celularity
N/A
0.25
0.19
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/A
12.52
12.52
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
0.90
0.90
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Celularity, Inc. stock logo
CELU
Celularity
19.02%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
90.20%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
82.95%

Insider Ownership

CompanyInsider Ownership
Celularity, Inc. stock logo
CELU
Celularity
22.10%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
7.57%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
27.18%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
64.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celularity, Inc. stock logo
CELU
Celularity
22026.69 million20.79 millionOptionable
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
5052.99 million48.98 millionOptionable
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
569.34 million50.49 millionOptionable
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
90126.75 million45.55 millionNot Optionable

Recent News About These Companies

Brain health
Treatment Trials in Alzheimer's Disease
Is Vaxxinity Inc (VAXX) Stock a Good Investment?
Why Is Vaxxinity (VAXX) Stock Up 39% Today?
Why Is Vaxxinity (VAXX) Stock Down 58% Today?
Vaxxinity Plans to Delist Shares From Nasdaq
Vaxxinity Issues Shareholder Letter
VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023
Vaxxinity, UF Join Forces Against Neurodegenerative Diseases

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celularity stock logo

Celularity NASDAQ:CELU

$2.06 -0.07 (-3.52%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

PMV Pharmaceuticals stock logo

PMV Pharmaceuticals NASDAQ:PMVP

$1.36 -0.03 (-1.80%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.65 -0.13 (-17.07%)
Closing price 03:59 PM Eastern
Extended Trading
$0.66 +0.01 (+1.69%)
As of 04:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Vaxxinity stock logo

Vaxxinity NASDAQ:VAXX

$0.02 +0.02 (+19,900.00%)
As of 10:18 AM Eastern

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.